Working together to deliver cell and gene therapies for people impacted by serious diseases Learn More Our inspiration Learn More Pipeline Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-50X Exploring the potential of ABO-50X for the treatment of genetic eye disorders. Learn More Latest News Jun 1, 2023 Abeona Therapeutics to Present at the Jefferies Healthcare Conference View Press Release May 22, 2023 Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 View Press Release May 16, 2023 Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) View Press Release View All Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
